Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium ...

For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

I have been living with stage IV kidney cancer for more than ten years. By now, I have had more CT scans, MRIs, PET scans, blood tests and follow-up appointments than I could ever count. You would ...

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.